Silvia Ravera

Dr. Silvia Ravera

Department of Experimental Medicine, University of Genoa, 16132 Genova, Italy
orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 March 2015 in Oncotarget
Verified
Journal Article
Open access
PDF file
GBGiovanna Bianchi
Giovanna Bianchi
RMRoberto Martella
Roberto Martella
Silvia RaveraSilvia Ravera
Silvia Ravera
CMCecilia Marini
Cecilia Marini
SCSelene Capitanio
Selene Capitanio
VLValter Longo
Valter Longo
Tumor chemoresistance is associated with high aerobic glycolysis rates and reduced oxidative phosphorylation, a phenomenon called “Warburg effect” whose reversal could impair the ability of a wide range of cancer cells to survive in the presence or absence of chemotherapy. In previous studies, Short-term-starvation (STS) was shown to protect normal cells and organs but to sensitize different cancer cell types to chemotherapy but the mechanisms responsible for these effects are poorly understood. We tested the cytotoxicity of Oxaliplatin (OXP) combined with a 48hour STS on the progression of CT26 colorectal tumors. STS potentiated the effects of OXP on the suppression of colon carcinoma growth and glucose uptake in both in vitro and in vivo models. In CT26 cells, STS down-regulated aerobic glycolysis, and glutaminolysis, while increasing oxidative phosphorylation. The STS-dependent increase in both Complex I and Complex II-dependent O2 consumption was associated with increased oxidative stress and reduced ATP synthesis. Chemotherapy caused additional toxicity, which was associated with increased succinate/Complex II-dependent O2 consumption, elevated oxidative stress and apoptosis .

15 November 2013 in Cell Cycle
Verified
Journal Article
Open access
CMCecilia Marini
Cecilia Marini
BSBarbara Salani
Barbara Salani
MMMichela Massollo
Michela Massollo
AAAdriana Agnese Amaro
Adriana Agnese Amaro
AEAlessia Isabella Esposito
Alessia Isabella Esposito
Gianmario SambucetiGianmario Sambuceti
Gianmario Sambuceti
Emerging evidence suggests that metformin, a widely used anti-diabetic drug, may be useful in the prevention and treatment of different cancers. In the present study, we demonstrate that metformin ...

25 August 2018 in Lasers in Medical Science
Verified
Journal Article
Closed access
PDF file
Andrea AmaroliAndrea Amaroli
Andrea Amaroli
Silvia RaveraSilvia Ravera
Silvia Ravera
FBFrancesca Baldini
Francesca Baldini
SBStefano Benedicenti
Stefano Benedicenti
IPIsabella Panfoli
Isabella Panfoli
LVLaura Vergani
Laura Vergani

13 July 2017 in Cancer Research
Verified
Journal Article
Closed access
PDF file
FPFrancesco Piacente
Francesco Piacente
Irene CaffaIrene Caffa
Irene Caffa
Silvia RaveraSilvia Ravera
Silvia Ravera
GSGiovanna Sociali
Giovanna Sociali
MPMario Passalacqua
Mario Passalacqua
ANAlessio Nencioni
Alessio Nencioni
In the last decade, substantial efforts have been made to identify NAD+ biosynthesis inhibitors, specifically against nicotinamide phosphoribosyltransferase (NAMPT), as preclinical studies indicate their potential efficacy as cancer drugs. However, the clinical activity of NAMPT inhibitors has proven limited, suggesting that alternative NAD+ production routes exploited by tumors confer resistance. Here, we show the gene encoding nicotinic acid phosphoribosyltransferase (NAPRT), a second NAD+-producing enzyme, is amplified and overexpressed in a subset of common types of cancer, including ovarian cancer, where NAPRT expression correlates with a BRCAness gene expression signature. Both NAPRT and NAMPT increased intracellular NAD+ levels. NAPRT silencing reduced energy status, protein synthesis, and cell size in ovarian and pancreatic cancer cells. NAPRT silencing sensitized cells to NAMPT inhibitors both in vitro and in vivo; similar results were obtained with the NAPRT inhibitor 2-hydroxynicotinic acid. Reducing NAPRT levels in a BRCA2-deficient cancer cell line exacerbated DNA damage in response to chemotherapeutics. In conclusion, NAPRT-dependent NAD+ biosynthesis contributes to cell metabolism and to the DNA repair process in a subset of tumors. This knowledge could be used to increase the efficacy of NAMPT inhibitors and chemotherapy. Cancer Res; 77(14); 3857–69. ©2017 AACR.

25 June 2013 in Scientific Reports
Verified
Journal Article
Open access
PDF file
BSBarbara Salani
Barbara Salani
CMCecilia Marini
Cecilia Marini
ARAlberto Del Rio
Alberto Del Rio
Silvia RaveraSilvia Ravera
Silvia Ravera
MMMichela Massollo
Michela Massollo
Gianmario SambucetiGianmario Sambuceti
Gianmario Sambuceti
The anti-hyperglycaemic drug metformin has important anticancer properties as shown by the direct inhibition of cancer cells proliferation. Tumor cells avidly use glucose as a source for energy production and cell building blocks. Critical to this phenotype is the production of glucose-6-phosphate (G6P), catalysed by hexokinases (HK) I and II, whose role in glucose retention and metabolism is highly advantageous for cell survival and proliferation. Here we show that metformin impairs the enzymatic function of HKI and II in Calu-1 cells. This inhibition virtually abolishes cell glucose uptake and phosphorylation as documented by the reduced entrapment of 18F-fluorodeoxyglucose. In-silico models indicate that this action is due to metformin capability to mimic G6P features by steadily binding its pocket in HKII. The impairment of this energy source results in mitochondrial depolarization and subsequent cell death. These results could represent a starting point to open effective strategies in cancer prevention and treatment.

1 January 2016 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
STSotiria Tavoulari
Sotiria Tavoulari
EMEleonora Margheritis
Eleonora Margheritis
ANAnu Nagarajan
Anu Nagarajan
DDDavid C. DeWitt
David C. DeWitt
YZYuan-Wei Zhang
Yuan-Wei Zhang
GRGary Rudnick
Gary Rudnick
In LeuT, a prokaryotic homolog of neurotransmitter transporters, Na+ stabilizes outward-open conformational states. We examined how each of the two LeuT Na+ binding sites contributes to Na+-dependent closure of the cytoplasmic pathway using biochemical and biophysical assays of conformation. Mutating either of two residues that contribute to the Na2 site completely prevented cytoplasmic closure in response to Na+, suggesting that Na2 is essential for this conformational change, whereas Na1 mutants retained Na+ responsiveness. However, mutation of Na1 residues also influenced the Na+-dependent conformational change in ways that varied depending on the position mutated. Computational analyses suggest those mutants influence the ability of Na1 binding to hydrate the substrate pathway and perturb an interaction network leading to the extracellular gate. Overall, the results demonstrate that occupation of Na2 stabilizes outward-facing conformations presumably through a direct interaction between Na+ and transmembrane helices 1 and 8, whereas Na+ binding at Na1 influences conformational change through a network of intermediary interactions. The results also provide evidence that N-terminal release and helix motions represent distinct steps in cytoplasmic pathway opening.